Fig. 3.

NDV and radiation combination therapy when combined with PD1 blockade improves anti-tumour efficacy in a dose-dependent manner:

(a) Mouse treatment scheme. 200,000 B16-F10 melanoma cells were implanted in the right flank of C57BL/6 mice (n = 6–8 mice per group). 9 days post-implantation, tumours were treated with five intratumoural administrations of NDV at 10⁷ pfu every two days vs. mock treatment and three i.p. injections of anti-PD1 every four days. Certain cohorts of the tumour-implanted mice received either 0, 5, 10 or 20 Gy of single fraction radiation. Tumour volumes were measured until mice reached a humane endpoint.

(b) Clinically complete regression rates, defined by the absence of a visible or palpable tumour, in response to treatment are plotted. Statistical analysis was conducted with the Mantel-Cox test. **** p < 0.0001.

(c) Individual tumour volume progressions.